Physician profile
Mohammad Al Efishat
NPI 1710312400
$21,776.06
in general payments reported to CMS, 2019-2025
32 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,643 · 2023: $900 · 2024: $17K · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $3,199 · Travel and Lodging: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,150.00 |
| Food and Beverage | $3,199.48 |
| Travel and Lodging | $2,783.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,183.54 | 2022-2024 | |
| Stryker Corporation | $750.85 | 2022 | |
| W. L. Gore & Associates, INC. | $744.67 | 2022-2024 | Gore Synecor Biomaterial |
| Kerecis Limited | $484.60 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Ethicon US, LLC | $395.42 | 2022-2025 | Echelon Flex, Echelon; Endopath, Monocryl |
| Medtronic, INC. | $354.46 | 2022-2025 | Emprint |
| Endomagnetics LTD | $216.38 | 2024 | Magseed, Magtrace |
| Kci USA, INC. | $179.39 | 2022-2023 | V.A.C. Veraflo, Prevena, V.A.C. Veraflo Cleanse Choice |
| Sanara Medtech INC. | $175.02 | 2023-2024 | Celleraterx |
| Integra Lifesciences Corporation | $167.10 | 2022 | |
| Becton, Dickinson and Company | $154.44 | 2023 | Phasix Mesh |
| Enterra Medical, INC. | $124.00 | 2025 | |
| Conmed Corporation | $123.49 | 2024 | Airseal |
| Atricure, INC. | $112.09 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System |
| Davol INC. | $67.43 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $57.34 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $54.86 | 2024-2025 | Exparel |
| Boston Scientific Corporation | $50.71 | 2024 | Spyglass Discover |
| Hologic Sales and Service, LLC | $48.69 | 2024 | Localizer, Coolseal Generator |
| Convatec INC. | $46.45 | 2024 | |
| Merck Sharp & Dohme LLC | $32.04 | 2024 | Keytruda |
| Histosonics, INC. | $25.93 | 2025 | |
| Dilon Technologies, INC. | $25.93 | 2024 | Hemoblast Bellows |
| Solventum Corporation | $25.71 | 2025 | V.A.C.Ulta, Prevena, V.A.C. Veraflo |
| Organogenesis INC. | $25.67 | 2023 | Puraply |
| Teleflex LLC | $25.40 | 2022 | |
| Evoke Pharma, INC. | $24.86 | 2023 | Gimoti |
| Braintree Laboratories, INC. | $21.50 | 2022 | |
| Smith+Nephew, INC. | $21.37 | 2022 | |
| Springworks Therapeutics, INC. | $20.99 | 2024 | Ogsiveo |
| Myriad Genetic Laboratories, INC. | $18.43 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Al Efishat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.